222 related articles for article (PubMed ID: 24344200)
21. T-lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in the neonate.
Toldi G; Treszl A; Pongor V; Gyarmati B; Tulassay T; Vásárhelyi B
Int Immunol; 2010 Sep; 22(9):769-74. PubMed ID: 20601376
[TBL] [Abstract][Full Text] [Related]
22. Activation of the KCa3.1 channel contributes to traumatic scratch injury-induced reactive astrogliosis through the JNK/c-Jun signaling pathway.
Yi M; Dou F; Lu Q; Yu Z; Chen H
Neurosci Lett; 2016 Jun; 624():62-71. PubMed ID: 27163196
[TBL] [Abstract][Full Text] [Related]
23. Acacetin blocks kv1.3 channels and inhibits human T cell activation.
Zhao N; Dong Q; Fu XX; Du LL; Cheng X; Du YM; Liao YH
Cell Physiol Biochem; 2014; 34(4):1359-72. PubMed ID: 25301362
[TBL] [Abstract][Full Text] [Related]
24. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes.
Ren YR; Pan F; Parvez S; Fleig A; Chong CR; Xu J; Dang Y; Zhang J; Jiang H; Penner R; Liu JO
PLoS One; 2008; 3(12):e4009. PubMed ID: 19104661
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
Hu L; Pennington M; Jiang Q; Whartenby KA; Calabresi PA
J Immunol; 2007 Oct; 179(7):4563-70. PubMed ID: 17878353
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of candesartan on KCa3.1 potassium channel expression and cell culture and proliferation in peripheral blood CD4
Li H; Zhao JL; Zhang YM; Han SX
Clin Exp Hypertens; 2018; 40(4):303-311. PubMed ID: 29388859
[TBL] [Abstract][Full Text] [Related]
27. Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels.
Toldi G; Vásárhelyi B; Kaposi A; Mészáros G; Pánczél P; Hosszufalusi N; Tulassay T; Treszl A
Immunol Lett; 2010 Sep; 133(1):35-41. PubMed ID: 20603149
[TBL] [Abstract][Full Text] [Related]
28. Periodic Membrane Potential and Ca
Papp F; Hajdu P; Tajti G; Toth A; Nagy E; Fazekas Z; Kovacs S; Vámosi G; Varga Z; Panyi G
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106594
[TBL] [Abstract][Full Text] [Related]
29. KCa3.1 and TRPM7 channels at the uropod regulate migration of activated human T cells.
Kuras Z; Yun YH; Chimote AA; Neumeier L; Conforti L
PLoS One; 2012; 7(8):e43859. PubMed ID: 22952790
[TBL] [Abstract][Full Text] [Related]
30. Crocin Improves the Endothelial Function Regulated by Kca3.1 Through ERK and Akt Signaling Pathways.
Yang H; Li X; Liu Y; Li X; Li X; Wu M; Lv X; Chunhua C; Ding X; Zhang Y
Cell Physiol Biochem; 2018; 46(2):765-780. PubMed ID: 29621746
[TBL] [Abstract][Full Text] [Related]
31. Different calcium influx characteristics upon Kv1.3 and IKCa1 potassium channel inhibition in T helper subsets.
Orbán C; Bajnok A; Vásárhelyi B; Tulassay T; Toldi G
Cytometry A; 2014 Jul; 85(7):636-41. PubMed ID: 24827427
[TBL] [Abstract][Full Text] [Related]
32. Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease.
Valverde P; Kawai T; Taubman MA
J Dent Res; 2005 Jun; 84(6):488-99. PubMed ID: 15914584
[TBL] [Abstract][Full Text] [Related]
33. Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization.
Glasgow NG; Povysheva NV; Azofeifa AM; Johnson JW
J Neurosci; 2017 Oct; 37(40):9686-9704. PubMed ID: 28877967
[TBL] [Abstract][Full Text] [Related]
34. Increased Interleukin-10 Expression by the Inhibition of Ca
Ohya S; Matsui M; Kajikuri J; Endo K; Kito H
J Pharmacol Exp Ther; 2021 Apr; 377(1):75-85. PubMed ID: 33504590
[TBL] [Abstract][Full Text] [Related]
35. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease.
Hua X; Deuse T; Chen YJ; Wulff H; Stubbendorff M; Köhler R; Miura H; Länger F; Reichenspurner H; Robbins RC; Schrepfer S
Transplantation; 2013 Jan; 95(2):285-92. PubMed ID: 23325003
[TBL] [Abstract][Full Text] [Related]
36. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
37. Alleviating airway inflammation by inhibiting ERK-NF-κB signaling pathway by blocking Kv1.3 channels.
Zhou QL; Wang TY; Li M; Shang YX
Int Immunopharmacol; 2018 Oct; 63():110-118. PubMed ID: 30077824
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis.
Di L; Srivastava S; Zhdanova O; Ding Y; Li Z; Wulff H; Lafaille M; Skolnik EY
Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1541-6. PubMed ID: 20080610
[TBL] [Abstract][Full Text] [Related]
39. Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma.
Yu ZH; Xu JR; Wang YX; Xu GN; Xu ZP; Yang K; Wu DZ; Cui YY; Chen HZ
Am J Respir Cell Mol Biol; 2013 Jun; 48(6):685-93. PubMed ID: 23492185
[TBL] [Abstract][Full Text] [Related]
40. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
